Health economics of lipid therapy;Gesundheitsokonomie der behandlung von fettstoffwechselstorungen

Herz

Volumn 25, Issue 5, 2000, Pages 476-486

  Windler, Eberhard ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cholesterol; Coronary artery disease; Cost effectiveness; Lipid therapy

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MOLSIDOMINE; NITRIC ACID DERIVATIVE; TRIACYLGLYCEROL; ANTILIPEMIC AGENT;

AGE; ALGORITHM; ANGINA PECTORIS; ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; HEALTH INSURANCE; HEART FAILURE; HEART INFARCTION; HUMAN; LIFE EXPECTANCY; LIFESTYLE; REIMBURSEMENT; REVIEW; SUDDEN DEATH; ADULT; AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HYPERLIPIDEMIA; HYPERTENSION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LIFE STYLE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 0033843273     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00001960     Document Type: Review

References (40)

1. Reduction in cardiovascular events during pravastatin atherosclerosis intervention program
2. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid
3. The West of Scotland coronary prevention study: Economic benefit analysis of primary prevention with pravastatin
4. 10-Year follow-up results from the Gottingen Risk Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men
5. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
6. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
7. Die Diabetesinterventionsstudie (DIS): Diabetesverlauf und mortalitat, eine bilanz 22 jahre nach diagnosestellung
8. The cost-effectiveness of intensive therapy for diabetes mellitus
9. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction
10. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symtomatic men with normal to moderately elevated serum cholesterol levels
11. High-density lipoproteins: Epidemiologic profile and risks of coronary artery disease
12. Impact of hypertension, diabetes and smoking on the effect of simvastatin on coronary events in coronary heart disease patients
13. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MNONICA Project populations
14. Smoking and cardiovascular disease
15. Zeitliche trends von herzinfarkt-morbiditat, -mortalitat, 28-tage-letalitat und medizinischer versorgung
16. Prevention of cardiovascular disease: From biomedical research to health policy
17. Effect of simvastatin on survival and coronary morbidity in coronary heart disease patients 65 or older
18. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study
19. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
20. Acute care costs of the oldest old. They cost less, their care intensity is less, and they go to nonteaching hospitals
21. Should treatment recommendations for lipid lowering drugs be based on absolut coronary risk or risk reductions?
22. Baseline characteristics in the cholesterol and recurrent events (CARE) trial of secondary prevention in patients with average serum cholesterol levels
23. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
24. Impact of cholesterol lowering on resource use and cost among patients with coronary heart disease (CHD): Results from 4S
25. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
26. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy
27. Five-hundred life-saving interventions and their cost-effectiveness
28. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
29. The Beta-Blocker Pooling Project (BBPP): Subgroup findings from randomized trials in post infarction patients
30. Coronary heart disease: Reducing the risk
31. Prevention of cardiovascular events and death with poravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
32. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial
33. Cost-effectiveness of populationwide educational approaches to reduce serum cholesterol levels
34. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33)
35. Cost-effectiveness of interventions to prevent or treat coronary heart disease
36. Myocardial infarction and coronary deaths in the world health organization MONICA project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents
37. Sekundarpravention der koronaren herzkrankkheit durch lipidtherapie
38. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
39. Beta blockade during and after myocardial infarction: An overview of the randomized trials